A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Lu G, Deguzman FR, Hollenbach SJ, et al.
Modeling and simulation (M&S) was employed to recommend doses for human Phase I studies of a direct Factor Xa (FXa) inhibitor, CS-3030. Predicted human.
Background
